Contrasting Pharma Mar (OTCMKTS:PHMMF) and B&M European Value Retail (OTCMKTS:BMRRY)

Pharma Mar (OTCMKTS:PHMMF) and B&M European Value Retail (OTCMKTS:BMRRY) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Pharma Mar and B&M European Value Retail, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharma Mar	0	0	0	1	4.00
B&M European Value Retail	0	1	0	0	2.00

Institutional & Insider Ownership

0.0% of B&M European Value Retail shares are held by institutional investors. 1.9% of Pharma Mar shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Pharma Mar has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500. Comparatively, B&M European Value Retail has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500.

Profitability

This table compares Pharma Mar and B&M European Value Retail’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pharma Mar	N/A	N/A	N/A
B&M European Value Retail	N/A	N/A	N/A

Valuation and Earnings

This table compares Pharma Mar and B&M European Value Retail”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharma Mar	$171.15 million	10.74	$1.23 million	N/A	N/A
B&M European Value Retail	$6.89 billion	0.49	$461.32 million	N/A	N/A

B&M European Value Retail has higher revenue and earnings than Pharma Mar.

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.

About B&M European Value Retail

B&M European Value Retail S.A. operates general merchandise and grocery stores. The company operates a chain of stores under the B&M, Heron Foods, and B&M Express in the United Kingdom; and stores under the B&M brand in France. It also provides property management services. The company was founded in 1978 and is based in Munsbach, Luxembourg.